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Abstract: Oligodendrocyte damage and loss are key features of multiple sclerosis (MS) pathology.
Oligodendrocytes appear to be particularly vulnerable to reactive oxygen species (ROS) and cytokines,
such as tumor necrosis factor-α (TNF), which induce cell death and prevent the differentiation
of oligodendrocyte progenitor cells (OPCs). Here, we investigated the efficacy of sulforaphane
(SFN), monomethyl fumarate (MMF) and Protandim to induce Nrf2-regulated antioxidant enzyme
expression, and protect oligodendrocytes against ROS-induced cell death and ROS-and TNF-mediated
inhibition of OPC differentiation. OLN-93 cells and primary rat oligodendrocytes were treated
with SFN, MMF or Protandim resulting in significant induction of Nrf2-driven (antioxidant)
proteins heme oygenase-1, nicotinamide adenine dinucleotide phosphate (NADPH): quinone
oxidoreductase-1 and p62/SQSTM1, as analysed by Western blotting. After incubation with the
compounds, oligodendrocytes were exposed to hydrogen peroxide. Protandim most potently
promoted oligodendrocyte cell survival as measured by live/death viability assay. Moreover,
OPCs were treated with Protandim or vehicle control prior to exposing them to TNF or hydrogen
peroxide for five days, which inhibited OPC differentiation. Protandim significantly promoted
OPC differentiation under influence of ROS, but not TNF. Protandim, a combination of five herbal
ingredients, potently induces antioxidants in oligodendrocytes and is able to protect oligodendrocytes
against oxidative stress by preventing ROS-induced cell death and promoting OPC differentiation.
Keywords: multiple sclerosis; reactive oxygen species; Nrf2; antioxidant enzymes
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS).
Histopathological hallmarks include focal demyelinated lesions characterized by oligodendrocyte
(OL) cell death, axonal damage, gliosis, microglial activation, and infiltration of lymphocytes and
macrophages [1,2]. In chronic demyelinating lesions in advanced stages of the disease, OL loss is
extensive and widespread [3–5]. As oligodendrocyte progenitor cells (OPCs) were detected in chronic
lesions [5,6], it appears that premyelinating OLs fail to differentiate and ensheath the axon with myelin
in chronic MS. Evidence is emerging that both pro-inflammatory cytokines and oxidative stress play a
key role in OL cell pathology in MS.
Over the past decade, studies have shown that ROS-induced oxidative damage to cells in the CNS
significantly contribute to demyelination and neurodegeneration in MS [7–9]. Markers of lipid and
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DNA oxidative damage have been detected in several CNS cells, including neurons, axons, myelin,
and OLs in early active lesions with the highest levels of expression in cells that morphologically
resembled apoptotic OLs [10,11]. Furthermore, expression of genes involved in ROS production, in
particular the subunits of ROS-synthesizing enzyme nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (NOX), were profoundly upregulated in cases of acute MS, specifically in activated
microglia and macrophages in close vicinity of OLs [12].
In vitro studies demonstrated enhanced susceptibility of OLs to ROS-induced oxidative damage
and cell death compared to astrocytes [13–15] and microglia [16,17]. OPCs are even more vulnerable
than mature OLs to oxidative stress in vitro [18–22]. Factors contributing to the increased susceptibility
of OLs to oxidative stress include the high intracellular iron content of the cells and relatively
low levels of endogenous antioxidant proteins, which are lower in OPCs compared with mature
OLs [14,15,23,24]. Furthermore, it was demonstrated that ROS are able to block OL maturation in vitro
by arresting them in the progenitor phase by decreasing the expression of genes involved in OL
differentiation and increasing the expression of genes known to inhibit differentiation [25]. Not only
ROS, but also cytokines, such as tumor necrosis factor-α (TNF), may contribute to OL pathology in
MS. In several studies, TNF was shown to selectively damage OLs and myelin in vitro [26,27] and
was toxic to OL cultures [28,29]. Furthermore, TNF inhibited the differentiation of OPCs into mature
OLs [30,31]. Although the mechanisms and time frame of ROS- and cytokine-induced cell death
may differ, it is conceivable that both factors contribute to OL pathology in MS. Thus, a therapeutic
compound that is able to protect OLs from both ROS- and cytokine-induced damage would have
clinical value in MS [32]. Activation of the nuclear factor erythroid-2 related factor-2 (Nrf2) pathway
involves the transcription of multiple (antioxidant) proteins, including heme oxygenase 1 (HO-1) and
NAD(P)H: quinone oxidoreductase 1 (NQO-1), which protect cells from ROS- and cytokine-induced
damage and cell death. Nrf2-activating compounds, like sulforaphane (SFN) [33–38], fumaric acid
esters [39–42], and Protandim® [43–45] are known to induce antioxidant enzymes in various cell
types, have cytoprotective properties and reduce clinical signs in the experimental autoimmune
encephalomyelitis animal model for MS. The fumaric acid ester dimethylfumarate (DMF) (and its
active metabolite monomethylfumarate (MMF), in particular, have shown efficacy in MS, as the
DMF-containing oral formulation Tecfidera™ was successful in two phase 3 clinical trials and is now
used in the clinic to treat relapsing-remitting MS patients.
Here, we explored the efficacy of these cytoprotective compounds in protecting OLs against an
oxidative and inflammatory insult. Our data showed that Protandim, a phytochemical compound
consisting of five herbal ingredients, robustly increased antioxidant protein production in primary rat
OLs. Treatment of Protandim protected OLs against oxidative insults and counteracted ROS-induced
inhibition of OPC differentiation. Altogether, the results indicate that Protandim may have therapeutic
potential for protecting OLs against oxidative insult in MS.
2. Materials and Methods
2.1. Cell Cultures
OLN-93 cells, a cell line established from spontaneously transformed rat brain glial cultures [46],
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS, Hyclone, Logan, UT, USA), penicillin, and streptomycin at 37 ◦C. OLN93 cells were
plated in 96-wells plates (25,000 cells/well; Greiner Bio-One, Frickenhausen, Germany) or 24-well
plates (50,000 cells/well; Greiner Bio-One). Primary Oligodendrocytes. Primary OLs were isolated
from 0-day-old to 2-day-old Sprague Dawley rats, as described previously [47]. Animal experiments
were approved by the Animal Experiments Review Board of the VU University Medical Center.
Isolated OPCs were plated in 96-well plates (25,000 cells/well; Greiner Bio-One), 24-well plates
(50,000 cells/well; Greiner Bio-One) or ibidi µ-Slide 8 well plates (30,000 cells/well; Ibidi, Martinsried,
Germany) pre-coated with poly-L-lysine (PLL, 5 µg/mL; Sigma-Aldrich, St. Louis, MO, USA) for
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functional, protein or immunocytochemical analysis, respectively. For the differentiation studies, OLs
were synchronized to OPCs by culturing in SATO medium [47] supplemented with the growth factors
bFGF-2 (10 ng/mL; Peprotech, Rocky Hill, NJ, USA) and PDGF-AA (10 ng/mL; Peprotech) for 2 days
before the cells were treated. For the studies with mature OLs, cells were directly incubated in SATO
medium supplemented with 0.5% fetal calf serum (FCS) and cultured for 7 days (Bodinco, Alkmaar,
the Netherlands). The plated OL cultures were estimated to be ~90% pure; ~5% of cells were astrocytes
and ~5% microglia.
2.2. Functional Analysis of Oligodendrocytes
Primary OLs were allowed to mature for 7 days in SATO medium supplemented with 0.5%
FCS. The cells were then treated for 24 h with sulforaphane (Sigma-Aldrich) (5 µM), monomethyl
fumarate (Sigma-Aldrich) (90 µM), Protandim (LifeVantage, Sandy, UT, USA) (60 µg/mL) or their
respective vehicle control, dimethylsulfoxide (DMSO) or ethanol (EtOH), followed by 4 h treatment
with tert-butyl hydrogen peroxide (Sigma-Aldrich) or glucose oxidase (1:750,000; Sigma-Aldrich),
two different methods of ROS exposure. Cell viability after tert-butyl hydrogen peroxide and glucose
oxidase treatment was assessed using the LIVE/DEAD viability/cytotoxicity kit (Invitrogen, Carlsbad,
CA, USA) according to manufacturer′s protocol. Fluorescent signals of alive and dead cells were
measured with a fluorometer (FLUOstar Galaxy, BMG Lab technologies, Offenburg, Germany) and
the ratio between live and dead cells was calculated. To assess the protective function of Protandim
on OPC maturation under the inhibitory influence of inflammation or oxidative stress, OPCs were
synchronized by growth factors for 2 days and subsequently treated with 30 µg/mL of Protandim
or EtOH, as vehicle control. After 24 h, the medium was removed and replaced by SATO medium
without vehicle control or Protandim, supplemented with 0.5% FCS in the absence or presence of
either 10 ng/mL TNF or 10 µM tert-butyl hydrogen peroxide for 5 days.
2.3. Immunocytochemistry
To ensure purity of OPC culture and to determine differentiation of OPCs under experimental
conditions, cells grown on PLL-coated ibidi slides were processed for detection of OL-specific antigens.
Briefly, cells fixed with 4% paraformaldehyde were blocked with 10% goat serum and 0.1% Triton-X in
phosphate-buffered saline (PBS) at room temperature for 45 min, and thereafter incubated with primary
antibody overnight at 4 ◦C. Cells were then washed with PBS and incubated with secondary antibody
for 30 min. After washing, cells were incubated with 4,6-diamidino-2-phenylidole (DAPI, 10 mg/mL;
Sigma-Aldrich, St. Louis, MO, USA) for 5 min, washed again and kept in PBS. Primary antibodies
used for the recognition of OL antigens were MBP (1:200) and Olig2 antibody (1:200), followed
by goat anti-rat IgG Alexa Fluor or goat anti-rabbit Alexa Fluor (see ”antibody characterization”
below). All secondary antibodies were diluted 1:200 in PBS with 1% goat serum and 0.1% Triton-X
(Sigma-Aldrich). Five random fields per ibidi well/coverslip were scanned using a 10x lens of a
Leica fluorescence microscope (DM6000), and the total number of cells, the number of cells labeled
with each antibody, and the total number of MBP+/Olig2+ cells or MBP−/Olig2+ cells per field were
counted with ImageJ and compared. These determinations were performed on cultures from three
separate preparations.
2.4. Western Blotting
Protein isolation from primary rat OLs was performed using Laemmli buffer. Western blotting was
performed, as described earlier [48,49]. Proteins were separated on 10% SDS-PAGE gels and transferred
to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Berkeley, CA, USA). After
blocking in Odyssey blocking buffer (LI-COR Biosciences, Lincoln, AK, USA), membranes were
incubated with primary antibodies overnight in Odyssey blocking buffer at 4 ◦C. Primary antibodies
were detected by incubation with appropriate IRDye secondary antibodies (LI-COR Biosciences)
for 1 h at room temperature in Odyssey blocking buffer and quantified using the Odyssey infrared
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imaging system (LI-COR Biosciences). Actin quantification was used to correct for total protein loading
variation. Primary antibodies used were rabbit anti-HO-1 (1:1000), mouse anti-NQO-1 (1:1000), mouse
anti-p62/SQSTM1 (1:1000) and mouse anti-actin (1:5000) (see “antibody characterization” below and
in Supplementary Table S1).
2.5. Antibody Characterization
Primary antibodies used were rat anti-MBP (catalog no. MCA409S; RRID: AB_325004;
Abd Serotec, Oxfordshire, UK), rabbit anti-Olig2 (catalog no. AB9610; RRID: AB_570666; Millipore,
Billerica, MA, USA), rabbit anti-HO-1 (catalog no. ADI-OSA-150F; RRID: AB_1505620; Enzo Life
Sciences, Farmingdale, NY, USA), mouse anti-NQO-1 (catalog no. ab28947; RRID: AB_881738; Abcam,
Cambridge, UK), and mouse anti-p62/SQSTM1 (catalog no. ab56416; RRID: AB_945626), mouse
anti-β-actin (catalog no. A5441; RRID: AB_476744; Sigma-Aldrich, St. Louis, MO, USA). The anti-MBP
antibody was previously shown to stain myelin membrane formation in rat oligodendrocytes isolated
from the brains of newborn pups using immunocytochemistry [50]. The anti-HO-1 antibody was
demonstrated to stain a band at ~32 kDa in primary rat cerebellar neurons, whilst the anti-NQO-1
antibody was shown to stain NQO-1 at ~30 kDa human oral squamous cell carcinomas [51]. Rat
pancreatic islet cells were stained by the anti-p62 antibody at approximately 62 kDa [52] and β-actin
in mouse brain cortical cells was identified by the anti-β-actin antibody at a height of 42 kDa in
a paper by Cheishvili et al. [53]. The secondary Alexa antibodies (goat anti-rat 488 (catalog no.
A-11006; RRID: AB_10561520; Thermo Fischer Scientific, Waltham, MA, USA), goat anti-mouse 555
(catalog No.A-21428; RRID: 2535849; Thermo Fischer Scientific) were used at 1:200 dilution.
2.6. Glutathione Assay
Cells were plated at 25,000 per well in a 96-well plate (Greiner Bio-One) and allowed to mature for
7 days in SATO medium supplemented with 0.5% FCS. Following 24 h treatment with sulforaphane
(5 µM), monomethyl fumarate (Sigma-Aldrich) (90 µM), Protandim (LifeVantage) (60 µg/mL), OLs
were washed with PBS, and total glutathione was measured in a white 96-wells plate (Greiner Bio-One),
using GSH-Glo, according to manufacturer’s instructions (Promega, Madison, WI, USA). Luminescence
was measured with a FLUOstar Galaxy fluorometer.
2.7. Statistical Analysis
Results were analyzed using one-way analysis of variance (ANOVA) or student’s t-test for an
average of 3 independent experiments. p < 0.05.
3. Results
3.1. SFN, MMF and Protandim Increase Antioxidant Enzymes and p62 Expression in OLN-93 Cells
OLN-93 cells most closely resemble 5-day to 10-day old (postnatal) cultured rat brain
oligodendrocytes in terms of their morphological features and antigenic properties. To investigate
and compare the efficacy of the Nrf2-activating compounds, and optimize compound concentrations
for further experiments with primary rat oligodendrocytes, we first incubated OLN-93 cells with
two different concentrations of SFN, MMF or Protandim or their respective vehicle control
(DMSO or EtOH) for 24 h. The concentrations used were based on prior publications with the
compounds [37,54,55] and dose-ranging experiments we performed in OLN-93 cells (data not shown).
The concentrations were well-tolerated by the OLN-93 cells. MMF and Protandim dose-dependently
increased the protein expression of HO-1 (Figure 1A) and NQO-1 (Figure 1B) compared to the highest
concentration of their respective vehicle control. SFN, MMF and Protandim significantly increased
HO-1 expression, whereas only SFN and Protandim significantly enhanced the expression of NQO-1.
Furthermore, only SFN and MMF increased the expression of p62 in OLN-93 cells significantly
(Figure 1C). Although 5 µM SFN appears to be optimal for both NQO-1 and p62 expression, a general
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dose-dependent trend can be observed with MMF and Protandim. Protein expression of HO-1,
NQO-1 and p62 under EtOH- or DMSO-treated conditions were comparable to each other and
untreated control.
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Figure 2. Sulforaphane and Protandim promote viability of OLN-93 cells under tert-butyl hydrogen 
peroxide-induced oxidative insult. OLN-93 cells were treated with 5 μM SFN, 90 μM MMF, 60 
μg/mL Protandim or their respective DMSO or EtOH vehicle control for 24 h. After removal of 
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Figure 1. Nrf2-activators dose-dependently increase antioxidant protein expression in OLN-93 cells.
HO-1 (A), NQO-1 (B) and p62 (C) protein expression levels after 24 h treatment in the OLN-93
oligodendrocyte cell line with 5 µM or 10 µM SFN, 45 µM or 90 µM MMF, 30 µg/mL or 60 µg/mL
Protandim or their respective DMSO or EtOH vehicle control. Protein levels were assayed by Western
blotting. Data are presented as percentage of control and expressed as the mean± SEM of 3 independent
experiments. All statistics reflect one-way ANOVA tests with post hoc Bonferroni correction; * p < 0.05,
** p < 0.01; *** p < 0.001.
3.2. SFN and Protandim Prevent ROS-Induced Cell Death of OLN-93 Cells
To elucidate the cytoprotective potential of SFN, MMF and Protandim to protect OLN-93 cells from
oxidative stress, the cells were incubated for 24 h with either SFN (5 µM), MMF (90 µM), Protandim
(60 µg/mL) or their respective vehicle control prior to exposing them to 200 µM tert-butyl hydrogen
peroxide for 4 h. OLN-93 cell viability under EtOH- or DMSO-treated conditions were comparable
to each other and untreated control. Furthermore, SFN and Protandim, but not MMF, significantly
increased survival of OLN-93 cells (SFN: 65% ± 4.25% vs. 16% ± 8% of vehicle control; Protandim:
56% ± 1.7% vs. 19% ± 5% of vehicle control) (Figure 2).
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Figure 2. Sulforaphane and Protandim promote viability of OLN-93 cells under tert-butyl hydrogen
peroxide-induced oxidative insult. OLN-93 cells were treated with 5 µM SFN, 90 µM MMF, 60 µg/mL
Protan im or th ir respective DMSO or EtOH vehicle control for 24 . After removal of medium, cells
were subsequently exposed to either control medium or medium with 200 µM tert-butyl hydrogen
peroxide. C ll viability was measured using an Invitrogen live/dead cytotoxicity kit. Data are presented
as percentage of co trol an expressed as the mean ± SEM of 3 i dependent experi ents. Statistics
reflect one-way ANOVA test with post hoc Bonferroni correction; ** p < 0.01.
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3.3. SFN and Protandim Increase Antioxidant Enzymes and p62 Expression in Mature Primary Rat OLs
To investigate the potency of Nrf2-activating compounds in enhancing antioxidant proteins and
p62 expression in mature primary rat OLs, we incubated mature rat OLs for 24 h with the most
potent and tolerable concentrations of SFN, MMF or Protandim or their respective vehicle control,
as determined by prior experiments with OLN-93 cells and viability assays with mature rat OLs.
The concentrations used were 5 µM of SFN, 90 µM of MMF and 60 µg/mL of Protandim. Both
SFN and Protandim significantly increased HO-1 protein expression in OLs, while NQO-1 and p62
protein levels were only significantly enhanced upon Protandim treatment. In contrast to OLN-93
cells, MMF treatment did not result in increased HO-1, NQO-1 and p62 protein expression (Figure 3).
Furthermore, protein expression of HO-1, NQO-1 and p62 under EtOH- or DMSO-treated conditions
were comparable to each other and untreated control.
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Figure 3. Nrf2-activators dose-dependently increase antioxidant protein expression in mature primary
rat OLs. HO-1, NQO-1 and p62 protein expression levels after 24 h treatment in mature primary rat
OLs, differentiated for 7 days, with 5 µM SFN, 90 µM MMF,30 µg/mL Protandim or their respective
DMSO or EtOH vehicle control. Protein levels were assayed by Western blotting. Data are presented
as percentage of control and expressed as the mean ± SEM of 3 independent experiments. Statistics
reflect one-way ANOVA test with post hoc Bonferroni correction; * p < 0.05.
3.4. Protandim Increases Glutathione Levels in Mature Primary Rat OLs and Protects OLs from ROS-Induced
Cell Death
Glutathione is one of the most abundant mammalian intracellular thiol-containing antioxidants
and represents a key buffer to maintain the cellular redox balance [56–58]. Hence, the capacity of
the Nrf2-activators to enhance glutathione levels in mature OLs was investigated by incubating the
cells for 24 h with SFN, MMF or Protandim or vehicle control. Protandim treatment significantly
increased glutathione levels in primary OLs (Figure 4). Glutathione levels under EtOH- or
DMSO-treated conditions were comparable to each other. To elucidate the cytoprotective potential of
the Nrf2-activating compounds, primary rat OLs were incubated for 24 h with SFN, MMF, Protandim
or vehicle control. Thereafter, the medium with compounds was removed and the cells exposed
to an oxidative attack for 4 h. Only Protandim increased the percentage viability of primary rat
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OLs compared with vehicle control under both tert-butyl hydrogen peroxide exposure (Protandim:
71% ± 2% vs. 30% ± 7.5% of vehicle control) and glucose oxidase exposure (Protandim: 62% ± 2.5%
vs. 20% ± 4.5% of vehicle control; Figure 5). OL viability under EtOH- or DMSO-treated conditions
were comparable to each other and untreated control.
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3.5. Protandim Promotes Differentiation of OPCs under Oxidative Conditions
In order to investigate the protective potential of SFN, MMF and Protandim on OPC differentiation
under oxidative stress and inflammation, we first determined the efficacy of the compounds to promote
antioxidant enzyme expression in OPCs. H ret , primary OPCs were incubated for 24 h with SFN
(5 µM), MMF (90 µM) and Protandim (30 µg/mL) or vehicle control. Protandim and SFN significantly
Antioxidants 2016, 5, 30 8 of 15
enhanced HO-1 protein expression in OPCs (Figure 6). NQO-1 levels were undetectable by Western
blotting in OPCs (data not shown). ROS are known to inhibit OPC differentiation [25]. Based on the
beneficial effects of Protandim, we next explored the potential of Protandim to promote differentiation
of OPCs under oxidative conditions. OPCs were incubated for 24 h with Protandim (30 µg/mL) or
vehicle control prior to 5 day exposure with medium containing 0.5% FCS or medium with 10 µM
tertbutyl-hydrogen peroxide and 0.5% FCS, but no vehicle control or Protandim. Exposure to 10 µM
tertbutyl-hydrogen peroxide resulted in significant and consistent inhibition of OPC maturation,
and did not result in significant OPC cell death (data not shown). The ratio of MBP-positive and
-negative Olig2-positive cells indicates the percentage of differentiated, MBP-expressing OLs per
condition. Protandim treatment slightly increased the percentage of MBP-positive OLs compared
to vehicle control under normal conditions (38% ± 3.35% and 31% ± 0.9%, respectively), but this
was not significant. Tert-butyl hydrogen peroxide treatment significantly reduced the percentage of
MBP-positive OLs compared to untreated vehicle control (25% ± 1.25% and 31% ± 0.9%, respectively).
Protandim treatment significantly enhanced the percentage of MBP-positive OLs compared to vehicle
control under oxidative stress (34% ± 1.25% and 25% ± 1.75%, respectively) (Figure 7). The percentage
of MBP-positive OLs in untreated medium was comparable to that in vehicle control-treated medium.
Inflammatory mediators, such as TNF, are known to inhibit OPC differentiation [30,31].
We incubated OPCs with Protandim (30 µg/mL) or vehicle control and subsequently exposed OPCs
to either control medium or medium containing 10 ng/mL TNF in the absence of vehicle control or
Protandim for 5 days. This low dosage did not lead to significant OPC cell death (data not shown).
TNF significantly decreased the percentage of MBP-positive OLs compared to untreated vehicle
control (20% ± 2% and 28% ± 2.8%, respectively). Protandim marginally increased the percentage
of MBP-positive oligodendrocytes compared to vehicle control upon TNF treatment (25% ± 2% and
20% ± 2%, respectively), albeit not significantly (Figure 8). The percentage of MBP-positive OLs in
untreated medium was comparable to that in vehicle control-treated medium.
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Figure 6. Nrf2-activators dose-dependently increase HO-1 protein expression in primary rat OPCs.
After 2 day de-differentiation of OLs with growth factors bFGF-2 and PDGF-AA, primary rat OPCs
were treated with 5 µM SFN, 90 µM MMF,30 µg/mL Protandim or their respective DMSO or EtOH
vehicle control for 24 h. Protein levels were assayed by Western blotting. Data are presented as
percentage of control and expressed as the mean ± SEM of 3 independent experiments. Statistics reflect
one-way ANOVA test with post hoc Bonferroni correction; * p < 0.05.
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Figure 8. Protandim marginally promotes differentiation of primary rat OPCs in the presence of TNF.
After 2 days of de-differentiation, primary rat OPCs were incubated with 30 µg/mL Protandim or
vehicle control (EtOH) for 24 h. After removal of medium, cells were subsequently exposed to either
control medium or medium with 10 ng/mL TNF for 5 days. MBP and Olig2 expression were assayed by
immunocytochemistry. Data are presented as percentage of control and expressed as the mean ± SEM
of 3 independent experiments. Statistics reflect student’s t-test, one-tailed; * p < 0.05.
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4. Discussion
In this study, we explored the efficacy of several cytoprotective compounds in protecting
OLs against an oxidative and inflammatory insult. We show that the cytoprotective compounds
sulforaphane (SFN), monomethyl fumarate (MMF) and Protandim increase the expression of proteins
involved in antioxidant protection in OLN-93 cells, whereas Protandim and SFN promote antioxidant
enzyme production in mature primary rat OLs and primary rat OPCs. Importantly, SFN and Protandim
pre-treatment rescued OLN-93 cells from an oxidative attack. Protandim, but not SFN, significantly
enhanced glutathione levels in primary rat OLs and rescued primary rat OLs from an oxidative insult.
It is known that pro-inflammatory mediators, such as TNF and ROS inhibit OPC differentiation [25,31].
Here, we show that Protandim, a well-defined combination of five widely studied herbal ingredients
and a potent inducer of the Nrf-2 pathway [44], attenuates ROS-induced OPC inhibition.
Early active demyelinating MS lesions are characterized by massive influx of monocyte-derived
macrophages and activated microglia. These inflammatory cells produce cytotoxic mediators,
such as ROS and inflammatory molecules, including TNF, resulting in OL damage and loss,
demyelination and axonal damage [1,2]. To date, evidence is accumulating that compounds boosting
endogenous antioxidant production show beneficial effects in various in vitro and in vivo models of
neuroinflammation and oxidative stress [33–37,42–45,59], including the experimental autoimmune
encephalomyelitis (EAE) animal model for MS [38,39,60]. In addition, as clinical efficacy of Tecfidera™
in MS was shown to be partly attributable to Nrf2-activation, it suggests that boosting the endogenous
antioxidant system in MS has therapeutic potential. Indeed, reports have shown that ROS-induced
oxidative damage may play a key role in demyelination in MS [7–12] and that Nrf2-driven genes are
upregulated in white matter lesions [61].
Notably, all three compounds investigated in our study increased the expression of the
cytoprotective proteins HO-1, NQO-1 and p62 in OLN-93 cells. Yet, only SFN and Protandim
pre-treatment were able to rescue OLN-93 cells from hydrogen peroxide-induced cell death.
This suggests that protein levels of HO-1, NQO-1 and p62 induced by MMF may have been insufficient
to prevent ROS-induced cell death. Using primary mature OLs we observed that Protandim treatment
resulted in a more pronounced increase in HO-1, NQO-1 and p62 protein expression compared with
MMF and SFN. In addition, Protandim treatment significantly increased intracellular glutathione
levels, whereas both MMF and SFN did not affect glutathione levels. Glutathione is the most abundant
mammalian intracellular thiol-containing antioxidant and represents a key buffer to maintain the
cellular redox balance [56–58]. Protandim pre-treatment, not MMF or SFN, protected mature primary
rat OLs from hydrogen peroxide- and glucose oxidase-induced cell death. These findings indicate that
high endogenous levels of glutathione might be essential in protecting OLs against an oxidative attack.
Furthermore, p62 was reported to have neuroprotective effects in SH-SY5Y neuroblastoma
cells against hydrogen peroxide-induced cell death [62]. This suggests that Protandim-mediated
upregulation of p62 in primary rat OLs may have played a role in their survival against ROS, but this
requires further research.
The high metabolic rate, large intracellular iron stores and relatively low levels of endogenous
antioxidants make OPCs particularly vulnerable to oxidative and inflammation-driven cell death and
injury. The low levels of antioxidant proteins in OPCs may potentially clarify why we could not detect
NQO-1 protein levels in primary rat OPCs [14,15,23,24]. Furthermore, ROS are known to hamper OPC
differentiation by enhanced expression of genes involved in inhibition of differentiation and decreased
expression of genes known to promote OPC differentiation. In our study, ROS also reduced OPC
differentiation, which is in line with the report by French and colleagues [25].
We show that Protandim pre-treatment was able to counteract ROS-induced inhibition of OPC
differentiation. Interestingly, even under normal conditions we observed a slight increase in the number
of mature oligodendrocytes upon exposure to Protandim, suggesting that Protandim, even in the
absence of an oxidative insult, might stimulate OPC maturation. Like free radicals, pro-inflammatory
cytokines, such as TNF, contribute to OPC cell damage and we observed a reduction in OPC
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differentiation upon TNF exposure, which was in line with previous reports [30,31]. In contrast
to the beneficial effects observed under oxidative conditions, Protandim treatment did not attenuate
TNF-mediated block of OPC differentiation.
Athough Protandim showed high potency in our rat OL cultures, and demonstrated efficacy
in animal models of cardiovascular disease [43,63], little is known about the pharmacodynamic and
pharmacokinetic properties. Protandim contains five herbal ingredients, including ashwagandha,
bacopa extract, green tea extract, silymarin, and curcumin, and several studies have shown that
Protandim is able to potently activate Nrf2-driven gene expression [44,45]. The therapeutic properties
of all five compounds have been reported previously [64–66], of which curcumin has been the most
thoroughly investigated [67–69]. Further research into the mode of action of Protandim is therefore
required in order to determine if the compound would be efficacious in animal models for MS and
MS patients.
5. Conclusions
Taken together, our findings indicate that Protandim effectively prevented ROS-driven
oligodendrocyte cell death and promoted OPC differentiation under oxidative conditions. Our in vitro
data warrants future research to further explore the therapeutic efficacy of Protandim in experimental
MS animal models.
Supplementary Materials: The following are available online at www.mdpi.com/2076-3921/5/3/30/s1. Table S1.
Antibody characterization.
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